Company Overview of University of California-San Francisco
University of California-San Francisco is an education institution offering programs such as biological, biomedical, pharmaceutical, nursing, social and behavioral sciences, dentistry, medicine, and nursing and pharmacy. The schools of the university include Continuing Medical Education, School of Dentistry, School of Medicine, School of Nursing, and School of Pharmacy. University of California- San Francisco was established in 1897 and is based in San Francisco, California. The university has endowment assets worth $873 million.
San Francisco, CA 94143
Founded in 2007
Key Executives for University of California-San Francisco
Professor of Tumor Biology and Cancer Research
Executive Director of News
Executive Director of Global Health Sciences
Compensation as of Fiscal Year 2014.
University of California-San Francisco Key Developments
UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment
Nov 25 14
OncoSec Medical Inc. has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. Recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. Interleukin-12 (IL-12) is an inflammatory cytokine believed to be a master regulator of the immune system, promoting up-regulation of both the innate and adaptive immune responses. More specifically, IL-12 stimulates the production of another cytokine, interferon gamma (IFN-), which results in the stimulation of antigen processing and presentation machinery, leading to increased TILs and anti-tumor cytotoxic T-cell (CTL) activity. ImmunoPulse, an investigational intratumoral immunotherapy, uses plasmid DNA that encodes for IL-12 and delivers it directly into the tumor using a proprietary electroporation device. Preclinical and clinical data suggest that local delivery and expression of IL-12 with ImmunoPulse promotes tumor immunogenicity and increases TILs without the toxicities associated with systemic IL-12 administration. Recent interim data from OncoSec's ongoing Phase II study have demonstrated that plasmid IL-12 electroporation treatment increases IFN- production and increased expression of genes related to antigen processing and presentation, including the expression of PD-L1.
University of California, San Francisco and the Centre for Drug Research and Development Signs Drug Development Agreement Collaboration to Take New Medications from Laboratory to Commercial Development Stage
Oct 16 14
University of California, San Francisco and The Centre for Drug Research and Development (CDRD), announced a collaborative affiliation to identify potential medications and develop them to the stage where they are commercially attractive to private sector partners. The agreement is designed to address a challenging problem in drug development: the so-called 'Valley of Death' between the discovery of a potential therapy and the point where it is of commercial interest to pharmaceutical or biotech companies or private sector investors. During this phase, the financial burden of continued research without return can often mean that a promising medication is never developed further. The collaboration is the first in the United States for CDRD, which has similar agreements with institutions around the world, including Oxford University and the Universities of Tokyo, and Sydney. A scientific team from CDRD will visit UCSF in November in order to explore specific collaborative opportunities with UCSF researchers. Researchers interested in meeting with CDRD to discuss possible collaborations are encouraged to contact Kaley Wilson, PhD, associate director of partnerships.
UC San Francisco Appoints Jennifer R. Grandis as Associate Vice Chancellor of Clinical and Translational Research to Begin in January 2015
Oct 7 14
Jennifer R. Grandis, MD, has been appointed as UC San Francisco's Associate Vice Chancellor of Clinical and Translational Research (AVC-CTR) on Oct. 6, 2014. She will begin her new post in January 2015 while also holding a faculty appointment as professor of Otolaryngology-Head and Neck Surgery. Jennifer will lead, manage and shape the strategic direction for broad elements of clinical and translational research enterprise including the Clinical & Translational Institute (CTSI). In addition, her responsibilities include serving as a liaison to national committees in the field and overseeing all aspects of clinical trials infrastructure and processes. Jennifer will be collaborating with multiple entities and other leaders on campus, including but not limited to, the Medical Center, the entire EVCP organization, the four Schools and Graduate Division, and key ORUs and centers on campus. Grandis will take over for Deborah Grady, MD, who served as the interim director of Clinical and Translational Science Institute (CTSI). Additionally, Grandis is Health Sciences Assistant Vice Chancellor for Research Program Integration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|